Oslo, 30 April 2024, the Board of Directors hereby calls for the Annual General Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo, Norway at 13:00 Hours (CEST) on 14 May 2024.

 

All documents regarding the Annual General Meeting are available at the Company's website: www.lytixbiopharma.com.

 

For further information, please see the Company's website or contact CFO Gjest Breistein. Please see below for contact details.

 

Gjest Breistein, CFO

E-mail: gjest.breistein@lytixbiopharma.com

Phone: +47 952 60 512

 

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

https://news.cision.com/lytix-biopharma-as/r/lytix-biopharma-as--notice-of-annual-general-meeting-on-14-may-2024,c3970415

https://mb.cision.com/Main/16482/3970415/2769272.pdf

https://mb.cision.com/Public/16482/3970415/ac0f70a6ce86601f.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English